The notices it replaced
- Reissues: PAR-17-122 NINDS Exploratory Clinical Trials (R01)
- 2 steps back: PAR-13-281 NINDS Exploratory Clinical Trials (R01)
- 3 steps back: PAR-10-199 NINDS Exploratory Clinical Trials (R01)
Replaced by PAR-21-236.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,493,525 in first-year total cost, median $807,858.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BDCN-W (55)]5
- Neurological Sciences and Disorders K Study Section[NSD-K]4
- Special Emphasis Panel[ZNS1 SRB-G (03)]1
- Special Emphasis Panel[ZNS1 SRB-G (04)]1
- Special Emphasis Panel[ZNS1 SRB-G (05)]1
Most frequent institutions
- UNIVERSITY OF ROCHESTER2
- HENNEPIN HEALTHCARE RESEARCH INSTITUTE1
- MASSACHUSETTS GENERAL HOSPITAL1
- MEDICAL UNIVERSITY OF SOUTH CAROLINA1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | A Safety and Efficacy study of AAV2-hAADC for AADC deficiency2R01NS094292-06A1 | BANKIEWICZ, KRYSTOF S | OHIO STATE UNIVERSITY, OH | $3,683,088 | ZNS1 |
| 2018 | Neurotrophin-3 gene therapy for Charcot-Marie-Tooth 1A1R01NS105986-01 · under PAR-17-122 | SAHENK, ZARIFE | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $1,375,170 | ZRG1 |
| 2018 | A futility trial of sirolimus in multiple system atrophy1R01NS107596-01 · under PAR-17-122 | KAUFMANN, HORACIOPALMA CARAZO, JOSE ALBERTO | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $807,858 | ZRG1 |
| 2018 | Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial1R01NS107887-01 · under PAR-17-122 | AWAD, ISSAM A | UNIVERSITY OF CHICAGO, IL | $806,009 | ZRG1 |
| 2018 | Investigation of Sleep in the Intensive Care Unit (ICU-SLEEP)1R01NS102190-01A1 · under PAR-17-122 | WESTOVER, MICHAEL BRANDON | MASSACHUSETTS GENERAL HOSPITAL, MA | $640,029 | ZRG1 |
| 2018 | Regenerative Peripheral Nerve Interface for Restoring Individual Finger Movement in People with Upper Limb Amputations1R01NS105132-01A1 · under PAR-17-122 | CHESTEK, CYNTHIA ANNE | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $406,598 | ZRG1 |
| 2017 | Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCC1U01NS095926-01A1 · under PAR-13-281 | BARSAN, WILLIAM GGAJEWSKI, BYRON J.ROCKSWOLD, GAYLAN L | HENNEPIN HEALTHCARE RESEARCH INSTITUTE, MN | $1,919,650 | NSD |
| 2017 | Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance1R01NS102176-01 · under PAR-13-281 | BIRBECK, GRETCHEN L. | UNIVERSITY OF ROCHESTER, NY | $690,395 | NSD |
| 2017 | STARFiSH: Study of Testosterone and rHGH in FSHD: A Proof-of-Concept Study1R01NS095813-01A1 · under PAR-13-281 | HEATWOLE, CHAD RYDEL | UNIVERSITY OF ROCHESTER, NY | $498,229 | NSD |
| 2017 | Hyperbaric Oxygen BrainInjury Treatment (HOBIT) Trial-SDMC1U01NS095814-01A1 · under PAR-13-281 | MARTIN, RENEE HEBERT | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $386,126 | NSD |
| 2016 | Preventing Epilepsy using Vigabatrin in Infants with Tuberous Sclerosis Complex1U01NS092595-01A1 · under PAR-13-281 | BEBIN, MARTINA | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $1,488,631 | ZNS1 |
| 2016 | A Safety and Efficacy study of AAV2-hAADC for AADC deficiency1R01NS094292-01 · under PAR-13-281 | BANKIEWICZ, KRYSTOF S | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $967,730 | ZNS1 |
| 2016 | Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)1R01NS094257-01A1 · under PAR-13-281 | PASCUAL, JUAN M. | UT SOUTHWESTERN MEDICAL CENTER, TX | $824,012 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.